Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
Completed
Meda Pharmaceuticals
Phase 3
2013-07-01
The purpose of this study is to determine if Dymista nasal spray is better and safer than
placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)
Unknown status
Universitaire Ziekenhuizen Leuven
Phase 4
2014-10-01
Comparative analysis of the efficacy of intranasal MP29-02 (a novel formulation of azelastine
and FP) has already been conducted in patients with moderate-to-severe seasonal AR. The
combination formulation appeared to be superior in these patients with better symptomatic
relief. However, objective analysis of the effect of this treatment on nasal mediators and/or
nasal hyperreactivity has not yet been performed and would help in understanding the
additional benefit of the combination treatment over monotherapy with nasal corticosteroids.
Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™
Unknown status
Teva Pharmaceuticals USA
Phase 3
2014-08-01
To evaluate the therapeutic equivalence of a test formulation of Azelastine hydrochloride and
Fluticasone propionate Nasal Spray to the reference listed drug, Dymista™ Nasal Spray in the
relief of the signs and symptoms of Seasonal Allergic Rhinitis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.